Alerta

BLOOD GLUCOSE MEASUREMENT METHOD, ELECTRONIC DEVICE, AND SYSTEM

Resumen de: EP4613192A1

A blood glucose measurement method, an electronic device (100), and a system are provided. The blood glucose measurement method includes: first determining a core temperature of a human body, determining a sensor temperature based on the core temperature, a skin temperature, and a physiological parameter, and performing temperature compensation on blood glucose measurement, to obtain a blood glucose concentration with higher accuracy.

SYSTEM AND METHOD FOR DETECTING PRESSURE INDUCED SENSOR ATTENUATIONS (PISAS) OF CONTINUOUS GLUCOSE MONITORING (CGM)

Resumen de: AU2023372542A1

Embodiments can relate to a system for automatically detecting sensor compression in continuous glucose monitoring including at least one sensor and at least one processor in communication with the at least one sensor, the at least one processor executing at least two machine learning models, wherein the at least one processor is programmed or configured to cause the processor to receive, from the at least one sensor, measurement data including at least one time series of blood glucose (BG) measurements measured by the at least one sensor, determine that the at least one time series of BG measurements is a candidate series including a compression artifact using a first machine learning model, and generate, using a second machine learning model, a signal output indicating that the at least one time series of BG measurements was obtained while the at least one sensor was subject to compression.

SYSTEM AND METHOD FOR DETECTING SENSOR COMPRESSION OF CONTINUOUS GLUCOSE MONITORING (CGM) SENSORS

Resumen de: AU2023372535A1

Embodiments can relate to systems and methods for automatically detecting sensor compression in continuous glucose monitoring in real time. A system may include at least one sensor and at least one processor in communication with the at least one sensor. The at least one processor is programmed or configured to cause the processor to retrieve first measurement data including at least one time series of blood glucose (BG) measurements, the at least one time series being measured by the at least one sensor while not subject to compression; receive, from the at least one sensor, second measurement data including at least one BG measurement; determine a clearance value between BG measurements based on the first measurement data and the second measurement data; and generate a signal output indicating that the at least one sensor is subject to compression based on the clearance value between BG measurements exceeding a predefined threshold.

INHIBITOR FOR GLUCOSE UPTAKE INTO RED BLOOD CELLS, SUPPRESSANT FOR GLUCOSE CONCENTRATION REDUCTION IN BLOOD-COLLECTING TUBE, AND BLOOD-COLLECTING TUBE INCLUDING SAME

Resumen de: EP4614152A1

An object of the present invention is to provide an agent for inhibiting glucose uptake into red blood cells and a blood collection tube that suppresses glucose concentration decrease. According to the present invention, there is provided an agent for inhibiting glucose uptake into red blood cells, including inosine as an active ingredient. The inhibition agent of the present invention can be used for suppressing a decrease in glucose concentration of whole blood collected in a blood collection tube. According to the present invention, there is also provided a blood collection tube including inosine in an internal space. The blood collection tube of the present invention can be used to measure a glucose concentration in blood. The blood collection tube of the present invention can further include a glycolysis inhibitor.

USE OF NON-INVASIVE GLUCOSE SENSORS AND GLUCOSE RATE OF CHANGE DATA IN AN INSULIN DELIVERY SYSTEM

Resumen de: CN120266218A

An invasive blood glucose sensor and a non-invasive blood glucose sensor may be used in combination to improve blood glucose management of a user. The rate of change (ROC) of blood glucose levels from a non-invasive blood glucose sensor may be used, rather than or in combination with the use of blood glucose levels from a user of the CGM. A basal insulin delivery rate to the user may be adjusted in response to ROC blood glucose level data from the non-invasive sensor. Blood glucose levels ROC from a non-invasive blood glucose sensor may be used to predict future blood glucose levels ROC for a user between operating cycles of the insulin delivery device and/or to identify possible hypoglycemia or hyperglycemia events. These predicted future blood glucose levels ROC may be used in a cost function of a control system of the insulin delivery device to select a base insulin delivery dose. Blood glucose level readings may be used to calibrate a non-invasive blood glucose level sensor.

MEDICATION INFUSION COMPONENTS AND SYSTEMS

Resumen de: EP4613319A2

This invention pertains to systems and components useful for infusing medications such as insulin. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

Glucose oxidase conjugated hydrogel

Resumen de: FI20245266A1

The present disclose concerns glucose oxidase conjugated hydrogels, in particular to hydrogels featuring a bifunctional polymer and glucose oxidase that are covalently attached to each other by photo-crosslinking.

Alarms And Alerts For Medication Delivery Devices And Related Systems And Methods

Resumen de: AU2025220713A1

Systems, methods, and devices provide alarms and alerts in an on-body networked diabetes management system. Methods may include receiving glucose sensor data from a continuous glucose monitor and determining a dosage of insulin delivery based at least in part on the glucose sensor data. The method may include detecting an alarm or alert condition, and sending a wireless communication regarding the alarm or alert condition to a remote user-interface device. The method may include triggering an audible, visual, or haptic alarm or alert on the insulin delivery device unless an acknowledgement of the alarm or alert condition is received within a predetermined period of time. Systems, methods, and devices provide alarms and alerts in an on-body networked diabetes management system. Methods may include receiving glucose sensor data from a continuous glucose monitor and determining a dosage of insulin delivery based at least in part on the glucose sensor data. The method may include detecting an alarm or alert condition, and sending a wireless communication regarding the alarm or alert condition to a remote user-interface device. The method may include triggering an audible, visual, or haptic alarm or alert on the insulin delivery device unless an acknowledgement of the alarm or alert condition is received within a predetermined period of time. ug y s t e m s , m e t h o d s , a n d d e v i c e s p r o v i d e a l a r m s a n d a l e r t s i n a n o n - b o d y n e t w o r k e d u g

THERAPEUTIC METHODS AND DEVICES

Resumen de: US2025276127A1

The present invention relates to a novel medical use of glucagon, and other compounds with glucagon activity, as vasodilators, to assist in the delivery of therapeutic agents or in the operation of sensor devices which determine the level of analytes in the blood. In particular, the compound is administered in temporal coordination with the active agent and/or in conjunction with determination of the analyte by a bodily sensor, and at a site which is in the vicinity of the site of administration of the active agent and/or of the site(s) of sensing of the analyte by the bodily sensor. This includes in particular the delivery of insulin in the treatment of diabetes, and the determination of blood glucose levels by glucose sensors. Also provided herein are integrated systems for performing the medical uses and therapies.

BLOOD GLUCOSE MANAGEMENT SYSTEM

Resumen de: US2025275698A1

A biological property testing device includes a base comprising a primary surface extending in a base plane, and a first lancet station supported by the base. A first test strip channel provided in the base can have a main channel portion extending generally parallel with the base plane, and an angled channel portion that forms an angle with the main channel portion between 5 degrees and 90 degrees. The first test strip channel can house a biological test strip oriented so that a meter connecting end of the biological test strip is adjacent to the main channel portion and a sample end of the biological test strip is adjacent to the angled channel portion.

PERSONALIZED EVENT DETECTION METHODS AND RELATED DEVICES AND SYSTEMS

Resumen de: US2025279181A1

Techniques for detection of occurrence of a meal are provided. In some embodiments, the techniques may involve obtaining a plurality of glucose measurements indicative of a glucose level in a body of a patient during an analysis interval. The techniques may further involve detecting an occurrence of a meal during the analysis interval based on the plurality of glucose measurements obtained during the analysis interval. The techniques may further involve updating a user interface to include an indication of the meal detected during the analysis interval.

SENSOR APPLICATOR ASSEMBLY FOR CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: US2025275721A1

The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.

BIOSENSOR RELIABILITY JUDGMENT METHOD FOR WEARABLE DEVICES

Resumen de: US2025275722A1

Wearable electronic devices can be equipped with sensors to measure heart rate, blood oxygen level, respiratory rate, blood pressure, blood sugar level, and skin temperature. The device can include graphene-based sensors to measure heart rate, blood oxygen level, respiratory rate, blood pressure, blood sugar level, and skin temperature. The device may include a process for judging the reliability of biological sensor measurements using a capacitance measurement. The capacitance measurement can be conducted on the device and can determine the quality of contact between the device and the wearer. The device can display warnings to the wearer when the quality of contact between the device and its wearer is not sufficient to conduct a reliable biological sensor measurement.

METHOD OF MANUFACTURING A METABOLIC SENSOR

Resumen de: US2025275695A1

A method of manufacturing a metabolic sensor includes assembling a working wire for a metabolic sensor and exposing the interference layer to an oxidizing agent. The exposing is performed prior to sterilizing the working wire. The assembling comprises forming an interference layer on a substrate, the substrate having an electrically conductive surface; forming an enzyme layer on the interference layer, and forming a glucose limiting layer on the enzyme layer.

ANALYTE SENSORS AND SENSING METHODS FEATURING DUAL DETECTION OF GLUCOSE AND KETONES

Resumen de: MX2025009473A

Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.

OBSTETRICS DEVICE

Resumen de: BG113859A

The obstetric device contains a power supply battery module, a sensor unit, a minicomputer configuration (10 - server) and a transmitter of sensor information in digital form (9). The sensor unit includes in combination sensor elements for: pressure (1), sensing uterine activity through contractions and fetal motor activity; an ultrasound minigenerator and radiation receiver (2), using the Doppler effect when reflecting the signal from the contracting fetal heart muscle; an electronic sphygmomanometer or photoplethysmograph (6) for monitoring the mother's blood pressure; a reflex pulse oximeter for highly accurate determination of blood saturation and heart rate (pulse) of the mother (5, 7); a photo-acoustic spectrometer (8 - acoustic detector) for measuring the glucose level in the blood of the pregnant woman. The received sensory information from all non-electrical transducers is digitized and translated through an application on a local server (9 - smartphone) to a server (10) of a clinic or a treating gynecologist.

ACTIVE FANO RESONANCE BLOOD GLUCOSE SENSOR

Resumen de: WO2025175641A1

An active Fano resonance blood glucose sensor, relating to the field of non-invasive blood glucose monitoring. The blood glucose sensor comprises a resonator, an excitation layer, a low-noise amplifier (8) and a phase shifter (9), wherein the resonator, the low-noise amplifier (8) and the phase shifter (9) form a connection loop; the resonator is provided on the excitation layer; and the excitation layer is connected to an external excitation source. By using the phase shifter (9), the phase of an active circuit can be changed to selectively enhance resonance, improve the resonance Q factor, and realize detection of minor changes in blood glucose concentration, and thus the active Fano resonance blood glucose sensor can be applied to human blood glucose sensing and the problems in the prior art of poor stability and robustness. Moreover, by using the resonator and the excitation layer, self-reference error elimination can be achieved, significantly improving the performance of the microwave blood glucose sensor and improving the reliability of blood glucose measurement.

WEARABLE NONINVASIVE MICROWAVE GLUCOMETER

Resumen de: WO2025175650A1

The present disclosure relates to the field of noninvasive glucose monitoring, and specifically, to a wearable noninvasive microwave glucometer. According to the present disclosure, an active Fano resonance-based glucose sensor (11) and a glucose monitoring system (12) are integrated, such that the whole noninvasive microwave glucometer features compactness, wearability, and high sensitivity. Moreover, the active Fano resonance-based glucose sensor (11) monitors the blood glucose concentration on the basis of a microwave signal generated by a microwave signal generation-processing unit, and can thus achieve noninvasive, real-time glucose monitoring in a human and hypoglycemia alarm. The arrangement of the active Fano resonance-based glucose sensor (11), a power supply unit (14), the microwave signal generation-processing unit, and a screen (15) can improve the resolution and sensitivity of blood glucose monitoring, thereby meeting the clinical precision requirements.

AUTOMATIC MEDICAMENT DELIVERY DEVICE UTILIZING LIMITED OR NO USER INPUT

Resumen de: WO2025178832A1

Exemplary embodiments relate to drug delivery devices, such as automated insulin delivery (AMD) devices. The described methods and apparatuses allow an AMD device to be initialized and/or operated with little or no user input. Exemplary logic initializes the AMD device to operate with known-safe drug delivery parameters that leverage the AMD device's ability to monitor blood glucose levels at short intervals and continuously deliver small amounts of insulin. The AMD then rapidly adapts the parameters and system constraints based on current and historical glucose measurements. Further embodiments provide for the detection of events that result in disturbances to glucose control, and to adaptation of alert frequency based on user behavior.

INFUSION DEVICES AND RELATED RESCUE DETECTION METHODS

Resumen de: US2025269113A1

Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device to deliver fluid to a body of a user involves obtaining measurement values for a physiological condition influenced by the fluid, autonomously operating the infusion device to deliver the fluid based at least in part on the measurement values, and detecting a nonactionable condition based on the measurement values. In response to detecting the nonactionable condition, delivery of the fluid is limited while maintaining autonomous operation of the infusion device. In one exemplary embodiment, the nonactionable condition is a rescue condition indicative of the user having consumed fast-acting carbohydrates, and thus insulin delivery may be automatically limited in response to detecting the rescue carbohydrate consumption.

TRANSDERMAL GLUCOSE MONITOR COVER

Resumen de: US2025268491A1

A cover apparatus for obstructing a transdermal glucose monitor from view includes a top wall shaped and a perimeter wall. The perimeter wall is coupled to and extends away from the top wall. The perimeter wall and the top wall define a cavity which is dimensioned and configured to receive the transdermal glucose monitor therein

WEARABLE DEVICE SUCH AS FOR GLUCOSE MEASUREMENT

Resumen de: US2025272940A1

Modulation-encoded light, using different spectral bin coded light components, can illuminate a stationary or moving (relative) target object or scene. Response signal processing can use information about the respective different time-varying modulation functions, to decode to recover information about a respective response parameter affected by the target object or scene. Electrical or optical modulation encoding can be used. LED-based spectroscopic analysis of a composition of a target (e.g., SpO2, glucose, etc.) can be performed; such can optionally include decoding of encoded optical modulation functions. Baffles or apertures or optics can be used, such as to constrain light provided by particular LEDs. Coded light illumination can be used with a focal plane array light imager receiving response light for inspecting a moving semiconductor or other target. Encoding can use orthogonal functions, such as an RGB illumination sequence, or a sequence of combinations of spectrally contiguous or non-contiguous colors.

ANALYTE SENSORS AND SENSING METHODS FEATURING DUAL DETECTION OF GLUCOSE AND KETONES

Resumen de: EP4606303A1

Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.

Investigation of glycemic events in blood glucose data

Resumen de: US12396664B1

To better understand the impact of glycemic events, some entities have begun examining the relationship between the blood glucose level and another physiological parameter. However, this relationship can be difficult to understand. Introduced here are computer programs and associated computer-implemented techniques for discovering glycemic events in a series of data values representative of blood glucose measurements and then altering the measurement schedule of a sensor capable of generating measurements in a dimension other than blood glucose based on the glycemic events. By altering the measurement schedule of the sensor, a diabetes management platform can better understand how, if at all, dimensions other than blood glucose are related to the glycemic health state of a subject whose blood glucose level is being monitored.

ANALYTE LEVEL CALIBRATION USING BASELINE ANALYTE LEVEL

Nº publicación: US2025261885A1 21/08/2025

Solicitante:

ABBOTT DIABETES CARE INC [US]
ABBOTT DIABETES CARE INC

Resumen de: US2025261885A1

Methods, computers, and systems used to improve accuracy of glucose level measurement of an in vivo positioned sensor are disclosed herein. The method includes collecting signal data from an in vivo positioned sensor over a period of time, wherein the signal data is indicative of glucose levels, analyzing the collected signal data and identifying signal data points that occur most frequently within the collected data, correlating the identified signal data points to a normal physiological level for glucose, the identified signal data points being taken from the signal data collected from the in vivo positioned sensor, and deriving glucose levels from the collected signal data using the identified signal data points as a reference point for the normal physiological level of the glucose for a user of the in vivo positioned sensor